[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,224,086
  • Shares Outstanding, K 48,881
  • Annual Sales, $ 109,790 K
  • Annual Income, $ -153,490 K
  • EBIT $ -67 M
  • EBITDA $ -68 M
  • 60-Month Beta 1.57
  • Price/Sales 20.45
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 72.52% (-2.60%)
  • Historical Volatility 64.30%
  • IV Percentile 6%
  • IV Rank 30.75%
  • IV High 188.55% on 03/20/26
  • IV Low 21.00% on 08/26/26
  • Expected Move (DTE 21) 2.02 (4.64%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 132
  • Volume Avg (30-Day) 427
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 6,752
  • Open Int (30-Day) 6,975
  • Expected Range 41.60 to 45.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.38
  • Number of Estimates 4
  • High Estimate $1.34
  • Low Estimate $-0.07
  • Prior Year $-0.69
  • Growth Rate Est. (year over year) +155.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.68 +18.92%
on 08/03/26
50.81 -14.15%
on 08/19/26
+2.74 (+6.70%)
since 07/28/26
3-Month
26.00 +67.77%
on 06/01/26
50.81 -14.15%
on 08/19/26
+14.93 (+52.04%)
since 05/28/26
52-Week
15.86 +175.03%
on 10/10/25
50.81 -14.15%
on 08/19/26
+24.38 (+126.72%)
since 08/28/25

Most Recent Stories

More News
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

NAZARETH, Israel , Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option...

URGN : 43.62 (-4.13%)
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

URGN : 43.62 (-4.13%)
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive...

URGN : 43.62 (-4.13%)
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 43.62 (-4.13%)
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

PRINCETON, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 43.62 (-4.13%)
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July...

URGN : 43.62 (-4.13%)
UroGen Pharma's Valuation Assumes Operating Leverage That Tomorrow's Report May Not Yet Prove

Barchart Research What to Expect from URGN Earnings URGN Generated August 4, 2026 Current Price $39.92 EPS Estimate $$-0.38 Consensus Rating Strong Buy Average Move 7.90% UroGen Pharma's Valuation Assumes...

URGN : 43.62 (-4.13%)
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 43.62 (-4.13%)
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET

URGN : 43.62 (-4.13%)
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027

UroGen Pharma (URGN) has surged nearly 180% over the past year and has strong technical momentum. URGN maintains a 100% “Buy” technical opinion from Barchart. The company’s revenue is projected to...

URGN : 43.62 (-4.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

3rd Resistance Point 47.12
2nd Resistance Point 46.33
1st Resistance Point 44.97
Last Price 43.62
1st Support Level 42.83
2nd Support Level 42.04
3rd Support Level 40.68

See More

52-Week High 50.81
Last Price 43.62
Fibonacci 61.8% 37.46
Fibonacci 50% 33.33
Fibonacci 38.2% 29.21
52-Week Low 15.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.